Boston, MA 08/12/2014 (wallstreetpr) – Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has announced that it is transferred from the NASDAQ capital market to the other trading platform which is The NASDAQ Global Market. There is no change in the symbol. It will continue to trade with the symbol ticker “TNXP” on the NASDAQ Global Market. It is a great achievement for the clinical-stage pharmaceutical company. It has successfully met the listing requirements of the NASDAQ Global Market. The company management is excited with the new development and expects to get more visibility in terms of potential investors.
The progress
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is the pharmaceutical company that manufactures effective drugs for the treatment of disorders pertaining to the central nervous system. It is busy in conducting the first trial of TNX-102 SL in fibromyalgia. Till this time, Fibromyalgia is known as a serious post-traumatic stress disorder with no adequate treatment options. The company will initiate a Phase 2 trial of TNX-102 SL in the last quarter of 2014. The new medication aims to eliminate the non-restorative sleep in a chronic bedtime treatment. It can minimize the pain and other related symptoms in fibromyalgia. It will work to improve the post-traumatic stress disorder symptoms.
The management view
During the release of second-quarterly results, M.D., president and CEO, Seth Lederman talked about the progress of the strategic corporate and clinical development plans. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) completed the enrollment in the BESTFIT trial in May. It was meant for the patients suffering from fibromyalgia. Tonix received the FDA approval for its Investigational New Drug application for PTSD. It can carry out the planned Phase 2 study, better known as the AtEase Trial. It expects to start the clinical studies of its new drug TNX-201 in the first quarter of 2015. Tonix made the key changes in its core development team and is well positioned to carry out its planned development programs.
